glp-1 and eye disease Ozempic Blindness: Should You Worry? Diabetic patients taking GLP-1s may
Description
Briefly, FFAs can reduce the tyrosine phosphorylation of insulin receptor substrate-1 by activating the serine/threonine kinase, thereby aggravating IR (151)
Clinical vigilance is advised, particularly for symptoms such as a neck mass, dysphagia, or persistent hoarseness
10.1196/annals.1402.018 21 Borka BalasR.MeliL
and C.Z
doi:10.1016/j.cmet.2013.04.008
Although all evaluated GLP-1RAs were associated with lower odds of SUD outcomes, the magnitude of association varied across some agents
